Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now displays an updated software revision tag, changing from v3.6.0 to v3.6.2. This reflects a platform update rather than a change to the study details or other user-facing content.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now explicitly indicates that recruitment is closed and adds new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study). A formatting update replaces the Interventions heading from 'Intervention / Treatment' to 'Intervention/Treatment' and updates the revision tag from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check26 days agoChange DetectedThe page now displays Revision: v3.5.5, indicating the latest documentation update has been applied.SummaryDifference0.0%

- Check48 days agoChange DetectedThe site update indicates a new software revision from v3.5.3 to v3.5.4, signaling an incremental platform upgrade. This change relates to the site’s underlying version and does not modify the visible content or features on the page.SummaryDifference0.0%

- Check62 days agoChange DetectedThe site revision has been updated from v3.5.2 to v3.5.3, indicating a new software release. This backend update does not alter the visible study details content on the page.SummaryDifference0.0%

- Check69 days agoChange DetectedUpdated the displayed region name for the Bordeaux site from “Nouvelle-Aquitaine” to “New Aquitaine,” while retaining the same city and postal code.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.